Plant lectin can target receptors containing sialic acid, exemplified by podoplanin, to inhibit transformed cell growth and migration

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Ochoa Alvarez, Jhon Alberto ^a   Krishnan, Harini ^a   Shen, Yongquan ^a   Acharya, Nimish K ^a   Han, Min ^a   McNulty, Dean E ^b   Hasegawa, Hitoki ^c   Hyodo, Toshinori ^c   Senga, Takeshi ^c   Geng, Jian Guo ^d   Kosciuk, Mary ^a   Shin, Seung S ^e   Goydos, James S ^e   Temiakov, Dmitry ^a   Nagele, Robert G ^a   Goldberg, Gary S ^a  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b GLAXOSMITHKLINE   (United States)

^c NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^e RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLANT LECTIN; PODOPLANIN; SIALIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CARCINOGENESIS; CELL GROWTH; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; GLYCOSYLATION; HUMAN; HUMAN CELL; MAACKIA; MAACKIA AMURENSIS; MELANOMA CELL; MICROENVIRONMENT; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAACKIA; MELANOMA; MEMBRANE GLYCOPROTEINS; MICE; MOLECULAR SEQUENCE DATA; N-ACETYLNEURAMINIC ACID; NECROSIS; NEOVASCULARIZATION, PATHOLOGIC; PLANT LECTINS; SRC-FAMILY KINASES;

MAACKIA AMURENSIS;

EID: 84864195447     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041845     Document Type: Article

References (87)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin. 61:: 69-90.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58:: 71-96.
3. Friedl P, Wolf K, (2003) Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 3:: 362-374.
4. Uong A, Zon LI, (2010) Melanocytes in development and cancer. J Cell Physiol 222:: 38-41.
5. Wicki A, Christofori G, (2007) The potential role of podoplanin in tumour invasion. Br J Cancer 96:: 1-5.
6. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, et al. (2004) A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 64:: 6652-6659.
7. Nelson MH, Dolder CR, (2006) Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother 40:: 261-269.
8. Bange J, Zwick E, Ullrich A, (2001) Molecular targets for breast cancer therapy and prevention. Nat Med 7:: 548-552.
9. Los M, Roodhart JM, Voest EE, (2007) Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 12:: 443-450.
10. Cui H, Lin Y, Yue L, Zhao X, Liu J, (2011) Differential expression of the alpha2,3-sialic acid residues in breast cancer is associated with metastatic potential. Oncol Rep 25:: 1365-1371.
11. Wang FL, Cui SX, Sun LP, Qu XJ, Xie YY, et al. (2009) High expression of alpha 2, 3-linked sialic acid residues is associated with the metastatic potential of human gastric cancer. Cancer Detect Prev 32:: 437-443.
12. Inagaki Y, Tang W, Guo Q, Kokudo N, Sugawara Y, et al. (2007) Sialoglycoconjugate expression in primary colorectal cancer and metastatic lymph node tissues. Hepatogastroenterology 54:: 53-57.
13. Shah MH, Telang SD, Shah PM, Patel PS, (2008) Tissue and serum alpha 2-3- and alpha 2-6-linkage specific sialylation changes in oral carcinogenesis. Glycoconj J 25:: 279-290.
14. Chovanec M, Plzak J, Betka J, Brabec J, Kodet R, et al. (2004) Comparative analysis of alpha2,3/2,6-linked N-acetylneuraminic acid and cytokeratin expression in head and neck squamous cell carcinoma. Oncol Rep 12:: 297-301.
15. Shen Y, Chen CS, Ichikawa H, Goldberg GS, (2010) SRC induces podoplanin expression to promote cell migration. J Biol Chem 285:: 9649-9656.
16. Gandarillas A, Scholl FG, Benito N, Gamallo C, Quintanilla M, (1997) Induction of PA2.26, a cell-surface antigen expressed by active fibroblasts, in mouse epidermal keratinocytes during carcinogenesis. Mol Carcinog 20:: 10-18.
17. Nose K, Saito H, Kuroki T, (1990) Isolation of a gene sequence induced later by tumor-promoting 12-O-tetradecanoylphorbol-13-acetate in mouse osteoblastic cells (MC3T3-E1) and expressed constitutively in ras-transformed cells. Cell Growth Differ 1:: 511-518.
18. Martin-Villar E, Yurrita MM, Fernandez-Munoz B, Quintanilla M, Renart J, (2009) Regulation of podoplanin/PA2.26 antigen expression in tumour cells. Involvement of calpain-mediated proteolysis. Int J Biochem Cell Biol 41:: 1421-1429.
19. Navarro A, Perez RE, Rezaiekhaligh MH, Mabry SM, Ekekezie II, (2010) Polarized Migration of Lymphatic Endothelial Cells is Critically Dependent on Podoplanin Regulation of Cdc42. Am J Physiol Lung Cell Mol Physiol.
20. Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, et al. (2006) Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 9:: 261-272.
21. Cortez MA, Nicoloso MS, Shimizu M, Rossi S, Gopisetty G, et al. (2010) miR-29b and miR-125a regulate podoplanin and suppress invasion in glioblastoma. Genes Chromosomes Cancer 49:: 981-990.
22. Martin-Villar E, Fernandez-Munoz B, Parsons M, Yurrita MM, Megias D, et al. (2010) Podoplanin Associates with CD44 to Promote Directional Cell Migration. Mol Biol Cell 21:: 4387-4399.
23. Martin-Villar E, Scholl FG, Gamallo C, Yurrita MM, Munoz-Guerra M, et al. (2005) Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int J Cancer 113:: 899-910.
24. Kono T, Shimoda M, Takahashi M, Matsumoto K, Yoshimoto T, et al. (2007) Immunohistochemical detection of the lymphatic marker podoplanin in diverse types of human cancer cells using a novel antibody. Int J Oncol 31:: 501-508.
25. Kawaguchi H, El Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, et al. (2008) Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 26:: 354-360.
26. Yuan P, Temam S, El Naggar A, Zhou X, Liu DD, et al. (2006) Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer 107:: 563-569.
27. Liang H, Wu H, Giorgadze TA, Sariya D, Bellucci KS, et al. (2007) Podoplanin is a highly sensitive and specific marker to distinguish primary skin adnexal carcinomas from adenocarcinomas metastatic to skin. Am J Surg Pathol 31:: 304-310.
28. Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK, et al. (2005) Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 166:: 913-921.
29. Kunita A, Kashima TG, Morishita Y, Fukayama M, Kato Y, et al. (2007) The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. Am J Pathol 170:: 1337-1347.
30. Scholl FG, Gamallo C, Vilaro S, Quintanilla M, (1999) Identification of PA2.26 antigen as a novel cell-surface mucin-type glycoprotein that induces plasma membrane extensions and increased motility in keratinocytes. J Cell Sci 112 (Pt 24):: 4601-4613.
31. Cueni LN, Detmar M, (2009) Galectin-8 interacts with podoplanin and modulates lymphatic endothelial cell functions. Exp Cell Res 315:: 1715-1723.
32. Christou CM, Pearce AC, Watson AA, Mistry AR, Pollitt AY, et al. (2008) Renal cells activate the platelet receptor CLEC-2 through podoplanin. Biochem J 411:: 133-140.
33. Suzuki-Inoue K, Kato Y, Inoue O, Kaneko MK, Mishima K, et al. (2007) Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem 282:: 25993-26001.
34. Witz IP, (2006) The involvement of selectins and their ligands in tumor-progression. Immunol Lett 104:: 89-93.
35. Witz IP, (2006) Tumor-microenvironment interactions: the selectin-selectin ligand axis in tumor-endothelium cross talk. Cancer Treat Res 130:: 125-140.
36. Ingrassia L, Camby I, Lefranc F, Mathieu V, Nshimyumukiza P, et al. (2006) Anti-galectin compounds as potential anti-cancer drugs. Curr Med Chem 13:: 3513-3527.
37. Hasan SS, Ashraf GM, Banu N, (2007) Galectins - potential targets for cancer therapy. Cancer Lett 253:: 25-33.
38. Kato Y, Kaneko MK, Kunita A, Ito H, Kameyama A, et al. (2008) Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci 99:: 54-61.
39. Nakazawa Y, Sato S, Naito M, Kato Y, Mishima K, et al. (2008) Tetraspanin family member CD9 inhibits Aggrus/podoplanin-induced platelet aggregation and suppresses pulmonary metastasis. Blood 112:: 1730-1739.
40. Johnson KA, Brown PH, (2010) Drug development for cancer chemoprevention: focus on molecular targets. Semin Oncol 37:: 345-358.
41. de Bono JS, Ashworth A, (2010) Translating cancer research into targeted therapeutics. Nature 467:: 543-549.
42. Cerna A, Janega P, Martanovic P, Lisy M, Babal P, (2002) Changes in sialic acid expression in the lung during intrauterine development of the human fetus. Acta Histochem 104:: 339-342.
43. Pryme IF, Dale TM, Tilrem P, (2007) Oral mistletoe lectins: a case for their use in cancer therapy. Cancer Therapy 5:: 287-300.
44. Beuth J, Schneider B, Schierholz JM, (2008) Impact of complementary treatment of breast cancer patients with standardized mistletoe extract during aftercare: a controlled multicenter comparative epidemiological cohort study. Anticancer Res 28:: 523-527.
45. Pusztai A, Bardocz S, Ewen SW, (2008) Uses of plant lectins in bioscience and biomedicine. Front Biosci 13:: 1130-1140.
46. Pryme IF, Bardocz S, Pusztai A, Ewen SW, (2006) Suppression of growth of tumour cell lines in vitro and tumours in vivo by mistletoe lectins. Histol Histopathol 21:: 285-299.
47. Liu B, Bian HJ, Bao JK, (2010) Plant lectins: potential antineoplastic drugs from bench to clinic. Cancer Lett 287:: 1-12.
48. Augustin M, Bock PR, Hanisch J, Karasmann M, Schneider B, (2005) Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland. Arzneimittelforschung 55:: 38-49.
49. Icirsch A, (2007) Successful treatment of metastatic melanoma with Viscum album extract (Iscador (R) M). J Alternative and Complementary Medicine 13:: 443-445.
50. De Mejia EG, Prisecaru VI, (2005) Lectins as bioactive plant proteins: a potential in cancer treatment. Crit Rev Food Sci Nutr 45:: 425-445.
51. Imberty A, Gautier C, Lescar J, Perez S, Wyns L, et al. (2000) An unusual carbohydrate binding site revealed by the structures of two Maackia amurensis lectins complexed with sialic acid-containing oligosaccharides. J Biol Chem 275:: 17541-17548.
52. Van Damme EJ, Van Leuven F, Peumans WJ, (1997) Isolation, characterization and molecular cloning of the bark lectins from Maackia amurensis. Glycoconj J 14:: 449-456.
53. Hotchkiss RS, Strasser A, McDunn JE, Swanson PE, (2009) Cell death N Engl J Med. 361:: 1570-1583.
54. Loos B, Engelbrecht AM, (2009) Cell death: a dynamic response concept. Autophagy 5:: 590-603.
55. Nicholson DW, (1999) Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ 6:: 1028-1042.
56. Edinger AL, Thompson CB, (2004) Death by design: apoptosis, necrosis and autophagy. Curr Opin Cell Biol 16:: 663-669.
57. Theiss C, Mazur A, Meller K, Mannherz HG, (2007) Changes in gap junction organization and decreased coupling during induced apoptosis in lens epithelial and NIH-3T3 cells. Exp Cell Res 313:: 38-52.
58. Pryme IF, Bardocz S, Pusztai A, Ewen SW, (1999) The growth of an established murine non-Hodgkin lymphoma tumour is limited by switching to a phytohaemagglutinin-containing diet. Cancer Lett 146:: 87-91.
59. Pryme IF, Bardocz S, Pusztai A, Ewen SW, (2002) Dietary mistletoe lectin supplementation and reduced growth of a murine non-Hodgkin lymphoma. Histol Histopathol 17:: 261-271.
60. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, et al. (1999) Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 155:: 739-752.
61. Kawaguchi T, Matsumoto I, Osawa T, (1974) Studies on hemagglutinins from Maackia amurensis seeds. J Biol Chem 249:: 2786-2792.
62. Yamamoto K, Konami Y, Irimura T, (1997) Sialic acid-binding motif of Maackia amurensis lectins. J Biochem 121:: 756-761.
63. Wang Q, Yu LG, Campbell BJ, Milton JD, Rhodes JM, (1998) Identification of intact peanut lectin in peripheral venous blood. Lancet 352:: 1831-1832.
64. Buonaccorsi JN, Plaza JA, (2012) Role of CD10, Wide-Spectrum Keratin, p63, and Podoplanin in the Distinction of Epithelioid and Spindle Cell Tumors of the Skin: An Immunohistochemical Study of 81 Cases. Am J Dermatopathol.
65. Yu H, Pinkus GS, Hornick JL, (2007) Diffuse membranous immunoreactivity for podoplanin (D2-40) distinguishes primary and metastatic seminomas from other germ cell tumors and metastatic neoplasms. Am J Clin Pathol 128:: 767-775.
66. Ogasawara S, Kaneko MK, Price JE, Kato Y, (2008) Characterization of anti-podoplanin monoclonal antibodies: critical epitopes for neutralizing the interaction between podoplanin and CLEC-2. Hybridoma (Larchmt.) 27:: 259-267.
67. Kato Y, Vaidyanathan G, Kaneko MK, Mishima K, Srivastava N, et al. (2010) Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas. Nucl Med Biol 37:: 785-794.
68. Pula B, Jethon A, Piotrowska A, Gomulkiewicz A, Owczarek T, et al. (2011) Podoplanin expression by cancer-associated fibroblasts predicts poor outcome in invasive ductal breast carcinoma. Histopathology 59:: 1249-1260.
69. Ito M, Ishii G, Nagai K, Maeda R, Nakano Y, et al. (2012) Prognostic impact of cancer-associated stromal cells in stage I lung adenocarcinoma patients. Chest.
70. Hoshino A, Ishii G, Ito T, Aoyagi K, Ohtaki Y, et al. (2011) Podoplanin-positive fibroblasts enhance lung adenocarcinoma tumor formation: podoplanin in fibroblast functions for tumor progression. Cancer Res 71:: 4769-4779.
71. Kawase A, Ishii G, Nagai K, Ito T, Nagano T, et al. (2008) Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma. Int J Cancer 123:: 1053-1059.
72. Wang H, Ng TB, Ooi VE, Liu WK, (2000) Effects of lectins with different carbohydrate-binding specificities on hepatoma, choriocarcinoma, melanoma and osteosarcoma cell lines. Int J Biochem Cell Biol 32:: 365-372.
73. Kapoor S, Marwaha R, Majumdar S, Ghosh S, (2008) Apoptosis induction by Maackia amurensis agglutinin in childhood acute lymphoblastic leukemic cells. Leuk Res 32:: 559-567.
74. Maenuma K, Yim M, Komatsu K, Hoshino M, Tachiki-Fujioka A, et al. (2009) A library of mutated Maackia amurensis hemagglutinin distinguishes putative glycoforms of immunoglobulin A1 from IgA nephropathy patients. J Proteome Res 8:: 3617-3624.
75. Maenuma K, Yim M, Komatsu K, Hoshino M, Takahashi Y, et al. (2008) Use of a library of mutated Maackia amurensis hemagglutinin for profiling the cell lineage and differentiation. Proteomics 8:: 3274-3283.
76. Fedoreev SA, Kulish NI, Glebko LI, Pokushalova TV, Veselova MV, et al. (2010) Maksar: A preparation based on amur maackia. Pharmaceutical Chemistry Journal 38:: 605-610.
77. Li X, Wang D, Xia MY, Wang ZH, Wang WN, et al. (2009) Cytotoxic prenylated flavonoids from the stem bark of Maackia amurensis. Chem Pharm Bull (Tokyo) 57:: 302-306.
78. Grimaldo S, Garcia M, Zhang H, Chen L, (2010) Specific role of lymphatic marker podoplanin in retinal pigment epithelial cells. Lymphology 43:: 128-134.
79. Ellis LM, Hicklin DJ, (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8:: 579-591.
80. Holmes K, Roberts OL, Thomas AM, Cross MJ, (2007) Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 19:: 2003-2012.
81. "llustrated Manual of China Main Plants- the Family Leguminosae,". Science Press, Beijing.
82. Crow DS, Kurata WE, Lau AF, (1992) Phosphorylation of connexin43 in cells containing mutant src oncogenes. Oncogene 7:: 999-1003
83. Estler M, Boskovic G, Denvir J, Miles S, Primerano DA, et al. (2008) Global analysis of gene expression changes during retinoic acid-induced growth arrest and differentiation of melanoma: comparison to differentially expressed genes in melanocytes vs melanoma. BMC Genomics 9:: 478.
84. Li X, Shen Y, Ichikawa H, Antes T, Goldberg GS, (2009) Regulation of miRNA expression by Src and contact normalization: effects on nonanchored cell growth and migration. Oncogene 28:: 4272-4283.
85. Shen Y, Jia Z, Nagele RG, Ichikawa H, Goldberg GS, (2006) SRC uses Cas to suppress Fhl1 in order to promote nonanchored growth and migration of tumor cells. Cancer Res 66:: 1543-1552.
86. Alexander DB, Ichikawa H, Bechberger JF, Valiunas V, Ohki M, et al. (2004) Normal cells control the growth of neighboring transformed cells independent of gap junctional communication and SRC activity. Cancer Res 64:: 1347-1358.
87. Li X, Jia Z, Shen Y, Ichikawa H, Jarvik J, et al. (2008) Coordinate suppression of Sdpr and Fhl1 expression in tumors of the breast, kidney, and prostate. Cancer Sci 99:: 1326-1333.